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The p53 tumor suppressor continues to be distinguished as the most frequently mutated 
gene in human cancer. It is widely believed that the ability of p53 to induce senescence 
and programmed cell death underlies the tumor suppressor functions of p53. However, 
p53 has a number of other functions that recent data strongly implicate in tumor sup-
pression, particularly with regard to the control of metabolism and ferroptosis (iron- and 
lipid-peroxide-mediated cell death) by p53. As reviewed here, the roles of p53 in the con-
trol of metabolism and ferroptosis are complex. Wild-type (WT) p53 negatively regulates 
lipid synthesis and glycolysis in normal and tumor cells, and positively regulates oxidative 
phosphorylation and lipid catabolism. Mutant p53 in tumor cells does the converse, pos-
itively regulating lipid synthesis and glycolysis. The role of p53 in ferroptosis is even more 
complex: in normal tissues, WT p53 appears to positively regulate ferroptosis, and this 
pathway appears to play a role in the ability of basal, unstressed p53 to suppress tumor 
initiation and development. In tumors, other regulators of ferroptosis supersede p53’s 
role, and WT p53 appears to play a limited role; instead, mutant p53 sensitizes tumor 
cells to ferroptosis. By clearly elucidating the roles of WT and mutant p53 in metabolism 
and ferroptosis, and establishing these roles in tumor suppression, emerging research 
promises to yield new therapeutic avenues for cancer and metabolic diseases.
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iNTRODUCTiON
The tumor suppressor gene TP53 has been the most heavily studied human gene since its discovery 
nearly 40 years ago (1). The main reason behind this status is the critical role p53 plays in preventing 
cancer development, and it is widely regarded as the “guardian of the genome.” For some time it has 
been generally believed that p53’s role in tumor suppression is by virtue of its ability to induce the 
apoptosis, cell cycle arrest, and senescence of pre-cancerous cells (2). However, it is now increasingly 
clear that p53 regulates many other pathways in the cell and that these other pathways also play roles 
in p53’s ability to function as a tumor suppressor (3). In particular, p53’s role in the regulation of 
genes involved in metabolism and ferroptosis has been implicated in its ability to suppress tumor 
development. Ferroptosis is a novel cell death pathway first characterized in 2012 and can be best 
described as an iron-dependent, caspase-independent form of cell death driven by the formation of 
FigURe 1 | The role of wild-type (WT) p53 in metabolism. Genes positively regulated by p53 are shown in green, and genes negatively regulated by p53 are shown 
in red. p53 inhibits glucose transport, glycolysis, and fatty acid synthesis while it promotes lipid uptake, fatty acid oxidation, oxidative phosphorylation, and 
glutaminolysis.
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lipid peroxidation (4). Specifically, two mouse models containing 
engineered mutations in p53 that eliminate the ability of p53 to 
induce apoptosis and senescence both retain the ability to suppress 
spontaneous tumor development; both of these mutants retain 
the ability to transactivate genes in metabolism and ferroptosis 
(5, 6). A summary of the data implicating p53 in the regulation 
of metabolism and ferroptosis is detailed below.
wiLD-TYPe (wT) p53 POSiTiveLY 
RegULATeS OXiDATive 
PHOSPHORYLATiON AND SUPPReSSeS 
gLUCOSe MeTABOLiSM
Wild-type p53 regulates the metabolic versatility of cells by 
favoring mitochondrial respiration over glycolysis, in part via 
the transactivation of SCO2 (cytochrome c oxidase assembly), 
which plays a direct role in oxidative phosphorylation (7). p53 also 
directly regulates the transactivation of GLS2 (Glutaminase 2); 
this enzyme allows glutamine usage as an energy source for 
the mitochondria (8). In addition, WT p53 negatively regulates 
glycolysis by transcriptionally repressing the glucose trans-
porters GLUT1 and GLUT4, and by transactivating RRAD and 
TIGAR; both are inhibitors of glycolysis (9–11). Finally, p53 also 
directly binds and inhibits the enzyme glucose-6-phosphate 
dehydrogenase, thus suppressing glucose metabolism (12). It 
is clear from these and other studies that in normal, unstressed 
organisms, p53 directly regulates the metabolic state in a cell 
(Figure 1). Not surprisingly, this gene and many of its regula-
tors are implicated in metabolic diseases, including obesity and 
diabetes (13).
MUTANT p53 POSiTiveLY RegULATeS 
wARBURg MeTABOLiSM (AeROBiC 
gLYCOLYSiS)
In contrast to the function of WT p53, mutant p53 in tumor cells 
favors aerobic glycolysis, in part by enhancing the trafficking of 
the glucose transporter GLUT1 to the plasma membrane, hence 
increasing glucose import (14, 15). Following the mutation of p53, 
the reduced levels of SCO2 and GLS2 and the increased levels of 
GLUT1 and GLUT4 favor aerobic glycolysis over oxidative phos-
phorylation. In this manner, mutant p53 is believed to contribute 
to the propensity of tumor cells to utilize aerobic glycolysis in favor 
of oxidative phosphorylation, or so-called Warburg metabolism 
(15). One of the hallmarks of cancer is deregulated metabolism, 
generally demonstrated by this switch from aerobic glycolysis to 
oxidative phosphorylation. Though this results in a lower and less 
efficient ATP yield, it is believed that cancer cells benefit by divert-
ing glycolytic intermediates to biosynthetic pathways necessary 
for rapid cell division (16). This metabolic switch also leads to 
decreased mitochondria-mediated apoptosis and more efficient 
signaling through available metabolites in cancer cells (17).
A COMMON geNeTiC vARiANT iN TP53 
iNFLUeNCeS iTS FUNCTiON iN 
MeTABOLiSM
There is a common coding region polymorphism of p53 at 
codon 72, encoding for either proline (P72) or arginine (R72). 
This amino acid variation can impact p53 function with regard 
to cell fate after stress. In response to DNA damage, the P72 
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variant of p53 predominantly triggers cell cycle arrest, while 
the R72 variant predominantly induces cell death, or apoptosis 
(18, 19). Despite these differences in function, the codon 72 
variation has not been consistently associated with cancer 
susceptibility (20). By contrast, in human studies this poly-
morphism is significantly associated with increased body mass 
index and risk for diabetes (21, 22). This premise is supported 
by studies in mice, where a mouse model for these codon 72 
variants shows increased high-fat diet-induced diabetes in mice 
with the R72 variant, compared to P72. In these studies, the 
p53 target genes TNFα and NPC1L1 were identified as critical 
regulators in the increase in diet-induced obesity in R72 mice 
(23). Interestingly, the R72 variant has also been shown to 
confer increased survival of cells in response to nutrient depri-
vation (24). These findings have led to the hypothesis that the 
R72 variant of p53 arose and was selected for as populations 
migrated north, where cold weather would require increased 
fat accumulation, but where survival in response to nutrient 
deprivation would also be under selection (24).
p53 RegULATeS LiPiD MeTABOLiSM
Though p53 is well known for regulating glycolysis and the citric 
acid cycle, p53 also has been shown to play a role in regulating 
lipid metabolism (25). It is believed that WT p53 enhances fatty 
acid oxidation while inhibiting fatty acid synthesis, thus acting 
as a negative regulator of lipid synthesis (25). There are several 
p53 target genes with roles in lipid metabolism. Sanchez-Macedo 
and colleagues demonstrated that carnitine palmitoyltransferase 
1C (CPT1C) is transcriptionally regulated by p53; this enzyme 
aids in the transport of activated fatty acids to the mitochondria. 
In support of a role for this p53-regulated gene in cancer, this 
group showed that Cpt1c-deficient mice display delayed tumor 
development and higher survival rates (26). Lipin 1 (LPIN1) is 
another p53 target gene; LPIN1 is necessary for proper adipocyte 
development and is induced under low nutrient conditions (27). 
Finck and colleagues showed that LPIN1 interacts with PGC-1α, 
another known p53 target gene with a role in metabolism, and 
that this interaction activates the expression of genes involved in 
promoting fatty acid oxidation (28).
In addition to directly regulating the transcription of genes 
involved in lipid metabolism, p53 can also regulate lipid metabo-
lism in a manner involving direct protein–protein interaction. 
For example, glucose-6-phosphate dehydrogenase, which is the 
rate-limiting enzyme in the pentose phosphate pathway, binds to 
and is directly inhibited by p53, resulting in decreased NADPH 
production and consequently decreased fatty acid synthesis (12). 
The sterol regulatory element-binding proteins (SREBP) family of 
transcription factors modulate the expression of genes involved 
in cholesterol, fatty acid, triacylglycerol, and phospholipid syn-
thesis (29–31). WT p53 represses SREBP function (32), while 
mutant forms of p53 bind directly to SREBP and enhance their 
transcriptional function, leading to increased SREBP activity in 
human tumors (33, 34). Consequently, mutant p53 is correlated 
with higher expression of sterol biosynthesis genes in human 
breast tumors (34, 35). Finally, AMP-activated protein kinase 
(AMPK) is an enzyme that is activated under low nutrient levels 
or energy stress and is known to inhibit fatty acid synthesis by 
interacting with acetyl-CoA-carboxylase and SREBP-1 (36, 37). 
Zhou and colleagues demonstrated that mutant p53 preferentially 
binds to and inhibits AMPK, leading to increased fatty acid syn-
thesis. As a result, mutant p53 proteins lead to increased AMPK 
signaling, contributing to invasive cell growth of tumor cells (33). 
A lesser explored area is the role of p53 in lipid transport. It has 
been shown that p53 transcriptionally regulates apolipoprotein B 
(apoB) and apoB editing enzyme complex 1, indicating the role 
of p53 in regulating atherogenic lipoproteins (38). Microarray 
analysis of human liver-derived cells identified phospholipid 
transfer protein, ATP binding cassette A12, and carboxyl ester 
lipase as three p53 target genes that all play a role in lipid trans-
port (39, 40). Overall, though it is clear that p53 plays a key role 
in mediating lipid synthesis and metabolism, the contribution of 
this pathway, and these p53 target genes, to tumor suppression by 
p53 remains to be determined (Figure 1).
FeRROPTOSiS iS A NOveL CeLL DeATH 
PATHwAY DRiveN BY LiPiD 
PeROXiDATiON
In 2012, Dixon and colleagues discovered a novel form of 
regulated cell death called ferroptosis. Ferroptosis is an iron-
dependent, caspase-independent form of cell death resulting 
from the accumulation of oxidized lipids (4, 41). This process is 
driven by the inactivation of glutathione peroxidase 4 (GPX4), 
an enzyme that is responsible for converting lethal lipid hydrop-
eroxides to non-toxic lipid alcohols, which requires glutathione 
in order to function (41). It is believed that peroxidation of 
polyunsaturated fatty acids (PUFAs) is the driving impetus for 
cell death by ferroptosis. PUFAs contain bis-allylic protons that 
can easily be abstracted and produce radicals that will react with 
oxygen, creating more radicals and resulting in a chain reaction 
of lipid reactive oxygen species (42). The exact mechanism of 
cell death by ferroptosis remains unknown, but one hypothesis 
is that the lipid damage leads to the destruction of the plasma 
membrane (43). It has been speculated that ferroptosis could 
be a mechanism of tumor suppression that works by eliminat-
ing cells that are nutrient deprived or have been exposed to an 
environmental stress or infection.
PHARMACOLOgiC RegULATiON OF 
FeRROPTOSiS
Ferroptosis can be induced using inhibitors of system xc− such 
as erastin, or analogs such as glutamate and sorafenib, which 
inhibit the import of cystine, resulting in depleted glutathione 
and subsequent inactivation of GPX4. Alternatively, ferroptosis 
can be induced by (1S,3R)-RSL3 (hereafter referred to as RSL3), 
which directly binds to and inhibits GPX4 (4, 5, 42). Buthione 
sulfoximine, FIN56, FINO2, CCl4, and cisplatin are other agents 
that have been demonstrated to induce ferroptosis in cells. Death 
by ferroptosis can be prevented by suppressing lipid peroxidation, 
which can be accomplished by using lipophilic antioxidants, such 
as ferrostatin-1, liproxstatin-1, or vitamin E. Iron chelators such 
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as deferoxamine or cicloprox are another tool used to suppress 
ferroptosis by reducing the levels of iron. Depleting PUFAs or 
adding monounsaturated fatty acids to cell culture media can also 
rescue cells from ferroptosis (42, 44).
FeRROPTOSiS iS iMPLiCATeD iN p53-
MeDiATeD TUMOR SUPPReSSiON
In 2012, Gu and colleagues developed a mouse model in which 
three normally acetylated lysine residues in the DNA-binding 
domain of p53 were mutated to arginine, and therefore could not 
be acetylated; this mouse is referred to as the 3KR mouse. Notably, 
cells from the 3KR mouse are unable to undergo p53-dependent 
apoptosis, cell cycle arrest, or senescence, and indeed the 3KR 
mutant of p53 fails to transactivate the majority of p53 target 
genes. Interestingly, this mouse model does not spontaneously 
develop cancer, implying that p53 could suppress tumor develop-
ment independent of senescence or apoptosis (45). This group 
found that the mutant 3KR protein retains the ability to undergo 
ferroptosis and regulate cystine metabolism by regulating the 
expression of the cystine importer SLC7A11; this suggested that 
ferroptosis might be one pathway that underlies p53-mediated 
tumor suppression. When wild type and 3KR MEFs were treated 
with the ferroptosis inducer Erastin, almost 50% cell death was 
observed whereas p53 null MEFs exhibited 20% cell death; this 
indicates that p53 sensitizes cells to ferroptosis, and also that other 
key regulators also play a role in ferroptosis (5). Subsequently, Gu 
and colleagues identified an additional acetylation site at lysine 
98 of p53, and they generated a mouse model in which all four 
acetylation sites were mutated to arginine (4KR). Interestingly, 
the 4KR mutant was unable to regulate genes involved in fer-
roptosis like SLC7A11, and unlike the 3KR mutant was unable to 
suppress tumor development (46). Though at present correlative, 
these data implicate the role of p53 in ferroptosis in its ability to 
suppress tumor development.
iN NON-TRANSFORMeD CeLLS, p53 
POSiTiveLY RegULATeS FeRROPTOSiS
In addition to SLC7A11, several other direct p53 target genes 
have been discovered to play a role in ferroptosis. These include 
GLS2, PTGS2, and SAT1. Studies from two separate groups sup-
port the role of GLS2 in ferroptosis, which is known to decrease 
glutathione and increase cellular ROS levels. Jiang and colleagues 
used ferroptosis inhibitors combined with glutaminolysis inhibi-
tors to inhibit Erastin-induced ferroptosis, thereby demonstrating 
that ferroptosis requires glutaminolysis and GLS2 (47). Murphy 
and colleagues showed that a polymorphic variant of p53 was 
able to induce growth arrest and senescence in both human and 
murine cells but failed to repress SLC7A11 or transactivate GLS2. 
This variant was markedly impaired at inducing ferroptosis and 
suppressing tumor development, thus again implicating the role 
of p53 in ferroptosis-mediated tumor suppression (48). Another 
p53 target gene with a role in ferroptosis is PTGS2, a gene encod-
ing the enzyme cyclooxygenase-2. Stockwell and colleagues first 
showed that the induction of ferroptosis using Erastin and RSL3 
led to the upregulation of PTGS2 (41). Notably, PTGS2 was not 
upregulated by ferroptosis inducers in p53-null cells, suggesting 
that this regulation is p53 dependent (5). Presently, the upregula-
tion of PTGS2 is widely used as a ferroptosis marker (5, 41).
A recent study by the Gu group showed that the p53 target 
gene SAT1 regulates ferroptosis (49). The authors identified 
SAT1 as a direct target of p53 and showed that silencing of SAT1 
reduced cell death induced by reactive oxygen species in cells 
with WT p53, but had no effect in p53-null cells. Mechanistically, 
this group showed that SAT1 increases the level and activity of 
arachidonate 15-lipoxygenase, an iron-binding enzyme that 
oxidizes PUFAs and increases lipid peroxidation. Notably, this 
study showed that neither p53 nor SAT1 alone appear to be suf-
ficient to induce ferroptosis. Instead, the combined data are more 
consistent with the premise that p53, by virtue of regulating genes 
that contribute to ferroptosis, regulates the sensitivity of cells to 
this pathway, rather than directly induces ferroptosis. Whether 
p53 regulates other genes involved in ferroptosis remains to be 
determined (Figure 2).
iN SOMe CeLLS, p53  NegATiveLY 
RegULATeS FeRROPTOSiS
A study recently published by Tarangelo and colleagues shows 
that p53 negatively regulates ferroptosis in cancer cells (50). This 
group found that pre-treating cells with Nutlin-3, a compound 
that stabilizes p53 delays the onset of ferroptosis in several cell 
types. The delayed onset of ferroptosis was found to depend 
on CDKN1A (encoding p21), a critical p53 transcriptional 
target. The mechanism through which p21 delays ferroptosis 
has yet to be elucidated, but it is believed that the conservation 
of intracellular glutathione may be a contributing factor for 
reduced ferroptosis sensitivity. The authors conclude that the 
p53–p21 axis enables cancer cells to survive under conditions 
of metabolic stress, such as cystine deprivation, by suppressing 
the onset of ferroptosis (50). A recent study showed that p53 
inhibits ferroptosis in colorectal cancer cells by binding to the 
enzyme dipeptidyl-peptidase-4 (DPP4), which is a modulator 
of ferroptosis and lipid metabolism. Mechanistically, this study 
showed that p53 antagonizes ferroptosis by sequestering DPP4 in 
a nuclear enzymatic inactive pool. In the absence of p53, DPP4 is 
free to interact with and form a complex with NOX1; this leads to 
increased lipid peroxidation and ferroptosis. Inhibition of DPP4 
suppresses ferroptosis significantly, whereas overexpression of 
DPP4 triggers Erastin sensitivity, particularly in p53-depleted 
cells (51). The bidirectional control of ferroptosis by p53 through 
transcription-dependent and transcription-independent mecha-
nisms may be context or cell-type dependent (Figure 2).
THe P47S POLYMORPHiSM OF TP53 
AFFeCTS FeRROPTOSiS AND TUMOR 
SUPPReSSiON
In addition to missense mutations, there are several functionally 
significant single-nucleotide polymorphisms (SNPs) in the TP53 
gene and other proteins known to regulate this pathway (such as 
FigURe 2 | The various roles of p53 in ferroptosis. Inhibition of glutathione peroxidase 4 (GPX4), the key enzyme that catalyzes the conversion of polyunsaturated 
fatty acids (PUFAs) containing peroxides to alcohols, is the key driver of ferroptosis. Depending on the context, p53 can suppress ferroptosis (such as in colorectal 
cancer cells) or promote ferroptosis. Mutant p53 sensitizes cells to ferroptosis even more than wild-type p53.
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MDM2 and MDM4). The Pro47Ser variant (hereafter S47) is the 
second most common SNP found in the p53 coding region (after 
Pro72Arg) that alters the amino acid sequence of the protein. 
To better elucidate the impact of this variant on p53 function 
and cancer risk, the Murphy group generated a humanized p53 
knock-in mouse model, in which exons 4–9 of murine p53 were 
replaced by human p53 exons containing either the wild type or 
the S47 variant (52–55). The majority of S47 mice spontaneously 
developed tumors of various histologic types, particularly liver 
cancer, between 12 and 18 months of age, unlike WT p53 mice 
(48). In mouse embryonic fibroblasts and human lymphoblas-
toid cell lines, the S47 variant showed impaired programmed 
cell death in response to cisplatin and other genotoxic stresses. 
Mechanistically, the S47 variant is defective for transactivation 
of genes involved in metabolism, such as Gls2 (glutaminase 2) 
and Sco2 (48). Consistent with the role of Gls2 in ferroptosis, 
this group found that S47 cells were markedly resistant to the 
ferroptosis-inducing agents Erastin and RSL3 (47, 48). This defect 
may contribute to the tumor-prone phenotype observed in S47 
mice.
MUTANT p53 SeNSiTiZeS TUMOR CeLLS 
TO FeRROPTOSiS
Wild-type p53 negatively regulates the expression of the cystine 
importer SLC7A11, which inhibits sensitivity to ferroptosis (5). 
Although this regulation occurs in normal cells, in tumor cells, 
other mediators of SLC7A11 appear to predominate in the regula-
tion of this gene. For example, the master antioxidant transcrip-
tion factor NRF2 can also regulate the expression of SLC7A11 at 
the transcriptional level, and NRF2 has been implicated as a key 
player in protecting cancer cells against ferroptosis. For example, 
inhibition of NRF2 in hepatocellular cancer cells increases the 
anti-cancer activity of Erastin and Sorafenib in vivo (56). Mutant 
forms of p53 can inhibit NRF2 function by direct interaction, 
and one group found that tumors with mutant p53 contain very 
low levels of SLC7A11, and thus show increased sensitivity to 
ferroptosis. Notably, overexpression of SLC7A11 in mutant p53 
models led to drug resistance, suggesting that levels of SLC7A11 
expression must be considered when targeting mutant p53 
driven cancers with ferroptosis-inducing compounds (57). In 
support of this premise, recent work in colorectal (CRC) cancer, 
where mutation or deletion of p53 is a frequent event, showed 
that human CRC cell lines harboring mutant p53 were far more 
sensitive to Erastin-mediated cell death when compared to CRC 
cells with WT p53. To validate these findings, they showed that 
knock in of a p53 hotspot mutation in both HCT116 and SW48 
cells restored sensitivity to Erastin (51). These data highlight a 
novel mechanism by which cancers driven by mutant p53 can be 
exploited using targeted therapy.
CONCLUSiON
The role of p53 in metabolism is quite clear and possibly even 
intuitively obvious: WT p53 limits glucose metabolism and lipid 
synthesis, while mutant p53 appears to do the opposite. The con-
tribution of its metabolic role to tumor suppression by p53, and 
to the ability of mutant p53 to drive tumor progression, remains 
to be unequivocally proven. The role of p53 in the regulation 
of ferroptosis, and the contribution of this function, to tumor 
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suppression is even less clear. While compelling data from mouse 
models supports the premise that p53 regulates the sensitivity 
of cells to ferroptosis, this may be restricted to the ability of 
basal p53 to suppress spontaneous tumor development, and in 
oncogene-stressed mouse models, it is clear that senescence and 
apoptosis play the predominant role. Similarly, p53 may regulate 
ferroptosis sensitivity in a cell type-specific manner. More stud-
ies in animal models, with attention to ferroptosis in different 
tissues, need to be done to more fully understand the role of p53 
in ferroptosis and ferroptosis in tumor suppression. Additionally, 
a clearer idea of what p53-target genes play a role in sensitivity 
to ferroptosis needs to be attained. Resolution of these questions 
should provide for much needed novel avenues to combat tumors 
with mutant p53.
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